Minerva Neurosciences (NASDAQ:NERV) Posts Earnings Results, Beats Estimates By $0.75 EPS

Minerva Neurosciences (NASDAQ:NERV) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.75, FiscalAI reports.

Here are the key takeaways from Minerva Neurosciences’ conference call:

• Minerva says their drug roluperidone (64 mg) produced statistically significant improvements in negative symptoms with effects visible by two weeks and also showed meaningful functional gains on the PSP scale that persisted in longer-term data.
• The company reports they achieved substantial FDA alignment — FDA recognizes the targeted monotherapy negative‑symptom population and agreed on a confirmatory trial design (including a one‑year descriptive relapse comparison), reducing regulatory uncertainty if the next trial is positive.
• Minerva completed a $200 million financing (≈$80M upfront, $120M in warrants) which management says funds the program through the Phase A topline readout and, if positive, supports subsequent submission and U.S. launch preparation.
• Management acknowledged prior mixed results (placebo pickup in the second trial) and emphasized execution risk — they reduced sample size to ~380, limited sites to ~40, and tightened rater training to control variability, but placebo/implementation risk remains material.

Minerva Neurosciences Trading Down 8.1%

Shares of Minerva Neurosciences stock opened at $7.30 on Thursday. The stock has a market capitalization of $315.87 million, a price-to-earnings ratio of -3.95 and a beta of -0.31. The firm’s 50-day moving average price is $5.34 and its two-hundred day moving average price is $4.00. Minerva Neurosciences has a 1-year low of $1.15 and a 1-year high of $12.46.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on NERV shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Monday, December 29th. Wall Street Zen upgraded Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $4.00.

Institutional Investors Weigh In On Minerva Neurosciences

Large investors have recently bought and sold shares of the business. Vivo Capital LLC bought a new position in Minerva Neurosciences in the 4th quarter valued at $17,377,000. State Street Corp grew its holdings in shares of Minerva Neurosciences by 45.4% during the fourth quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 7,500 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Minerva Neurosciences in the fourth quarter valued at $554,000. Ally Bridge Group NY LLC acquired a new stake in shares of Minerva Neurosciences in the fourth quarter valued at $6,655,000. Finally, Adage Capital Partners GP L.L.C. bought a new position in shares of Minerva Neurosciences in the fourth quarter valued at about $11,409,000. 34.56% of the stock is currently owned by institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.